2024
TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial
Everson R, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson B, Cloughesy T, Liau L, Prins R. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nature Communications 2024, 15: 3882. PMID: 38719809, PMCID: PMC11078958, DOI: 10.1038/s41467-024-48073-y.Peer-Reviewed Original ResearchConceptsAutologous tumor lysate-pulsed dendritic cellCD8+ T cellsT cellsPoly-ICLCTLR agonistsMalignant gliomasTumor lysate-pulsed dendritic cellsRandomized phase II trialCD4+ T cellsRandomized phase II clinical trialInterferon responsePhase II clinical trialPoly-ICLC treatmentDendritic cell vaccinesPD-1 expressionPhase II trialInterferon responsive gene expressionSystemic immune responsesImmune cell activationII clinical trialsInduction of interferon-inducible genesDelay disease progressionInterferon gene expressionInterferon-inducible genesPD-1
2020
CTIM-18. DENDRITIC CELL VACCINATION IN CONJUNCTION WITH ADJUVANT TLR-3 AGONIST ADMINISTRATION ENHANCES PRO-INFLAMMATORY IMMUNE RESPONSES AND IS ASSOCIATED WITH EXTENDED SURVIVAL IN MALIGNANT GLIOMA PATIENTS
Chavez C, Everson R, Orpilla J, Lee A, Khattab S, Antonios J, Salazar A, Cloughesy T, Liau L, Sun L, Hugo W, Prins R. CTIM-18. DENDRITIC CELL VACCINATION IN CONJUNCTION WITH ADJUVANT TLR-3 AGONIST ADMINISTRATION ENHANCES PRO-INFLAMMATORY IMMUNE RESPONSES AND IS ASSOCIATED WITH EXTENDED SURVIVAL IN MALIGNANT GLIOMA PATIENTS. Neuro-Oncology 2020, 22: ii36-ii37. PMCID: PMC7650313, DOI: 10.1093/neuonc/noaa215.152.Peer-Reviewed Original ResearchPatient's peripheral blood mononuclear cellsMalignant glioma patientsToll-like receptorsImmune responsePoly ICLCDendritic cellsClinical trialsTumor lysate-pulsed DCGlioma patientsTLR-3Lysate-pulsed DCPeripheral blood mononuclear cellsPhase II clinical trialTLR-7 agonistDendritic cell vaccinesPro-inflammatory immune responseWHO grade IIITLR-3 agonistIncreased expression of pro-inflammatory genesMGMT methylation statusBlood mononuclear cellsII clinical trialsExpression of pro-inflammatory genesPro-inflammatory responseExpression of pro-inflammatory factors